Product Code: 198005DB
The posttransplant administration of cyclophosphamide to prevent both graft-vs-host and host-vs-graft alloreactivity has revolutionized the practice of hematopoietic cell transplantation (HCT). The eligibility boundaries for consideration of HCT have expanded, and now include patients with a suitable haploidentical donor, instead of an HLA-identical sibling donor. This case study provides not only a simulation of treatment choices for a patient with multiple myeloma and end-stage renal disease, but also the background science that is helpful in understanding the clinical situation.
AABB thanks Thomas Spitzer, MD, for development of this case study.
AABB, 2019, digital, 5 pages
